Stock Market Reviews

ARQT (Arcutis Biotherapeutics, Inc.) News

Get the latest news, insights, and market updates on ARQT (Arcutis Biotherapeutics, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri
  Amit Munshi Amit Munshi, Arcutis Biotherapeutics WESTLAKE VILLAGE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Amit Munshi has been appointed to the Arcutis Board of Directors effective December 4, 2025, and announced the retirement of founder and long-serving Board member Bhaskar Chaudhuri, PhD. Dr. Chaudhuri will conti
  Dec 8, 2025 - $ARQT
• CAPR Stock Skyrockets 282% in a Week: Here's What You Need to Know
  Capricor Therapeutics stock soars after meeting key goals with statistical significance in a phase III study of deramiocel for Duchenne cardiomyopathy.
  Dec 5, 2025 - $ARQT
• ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study
  Absci Corporation stock jumps after initiating dosing in its phase I/IIa ABS-201 study for androgenetic alopecia, seeking early safety and efficacy signals.
  Dec 5, 2025 - $ARQT
• AZN's Baxdrostat Gets FDA Priority Tag for Uncontrolled Hypertension
  AstraZeneca's NDA for baxdrostat gains FDA priority review for treating hard-to-control hypertension. A decision is due in the second quarter of 2026.
  Dec 3, 2025 - $ARQT
• PCRX's Iovera Outperforms RFA Therapy in Pilot Study for Low Back Pain
  Pacira BioSciences' iovera shows stronger, longer-lasting relief than RFA in a pilot CLBP study, highlighting its tissue-sparing approach and potential spine-care impact.
  Dec 3, 2025 - $ARQT
• Is BrightSpring Health Services, Inc. (BTSG) Outperforming Other Medical Stocks This Year?
  Here is how BrightSpring Health Services, Inc. (BTSG) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
  Dec 3, 2025 - $ARQT
• Assessing Arcutis Biotherapeutics (ARQT) Valuation After Its Strong 1-Year Share Price Surge
  Arcutis Biotherapeutics (ARQT) has had a strong run lately, with the stock more than doubling over the past year. Investors are now asking whether the move reflects fundamentals or momentum. See our latest analysis for Arcutis Biotherapeutics. With the share price now at $29.96 and a 30 day share price return of 21.0 percent, on top of an 84.8 percent 90 day gain, Arcutis looks like a stock where upward momentum is clearly building and is being reinforced by a 137.6 percent 1 year total...
  Dec 3, 2025 - $ARQT
• MIRM Enrolls First Patient in Phase II Fragile X Syndrome Study
  Mirum enrolls the first participant in its phase II BLOOM study investigating MRM-3379 for treating Fragile X syndrome.
  Dec 2, 2025 - $ARQT
• Is the Options Market Predicting a Spike in Arcutis Biotherapeutics Stock?
  Investors need to pay close attention to ARQT stock based on the movements in the options market lately.
  Dec 2, 2025 - $ARQT
• ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know
  Arcturus Therapeutics' stock slides 59%, primarily due to mixed interim results from the phase II study of its investigational inhaled cystic fibrosis therapy, ARCT-032.
  Dec 1, 2025 - $ARQT